68 Ga-LNC-1007 PET/CT Imaging in a Patient With Renal Cell Carcinoma Compared With 68 Ga-PSMA-11 PET/CT

Clin Nucl Med. 2023 Dec 1;48(12):1119-1121. doi: 10.1097/RLU.0000000000004881. Epub 2023 Oct 7.

Abstract

A 57-year-old man was incidentally found with 3 lesions located in bilateral kidneys, which were finally diagnosed as renal cell carcinoma (RCC) by postoperative pathology. 68 Ga-LNC-1007, also denoted as 68 Ga-FAPI-RGD, was synthesized from fibroblast activation protein inhibitor-02 (FAPI-02) and cyclic arginine-glycine-aspartate (RGD), which could target both FAP and integrin α v β 3 . RCC lesions demonstrated only slight 68 Ga-PSMA uptake, but intense tracer uptake on 68 Ga-LNC-1007 PET/CT. This case demonstrates the potential value of 68 Ga-LNC-1007 PET/CT for the evaluation of RCC.

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Renal Cell* / pathology
  • Fluorodeoxyglucose F18
  • Humans
  • Kidney Neoplasms* / pathology
  • Male
  • Middle Aged
  • Oligopeptides
  • Positron Emission Tomography Computed Tomography / methods

Substances

  • PSMA-11
  • Gallium-68
  • Oligopeptides
  • Fluorodeoxyglucose F18